Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients

Marre, Michel; Gaal, Luc Van; Kh, Usadel; Ball, Michele; Whatmough, I.; Guitard, C

doi:10.1046/j.1463-1326.2002.00196.x

Cited by 59 publications

(41 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The association of nateglinide and metformin has already been proven to be an efficacious and safe antidiabetic strategy in type 2 diabetic patients (48). Its What is more specific in our study is the observation that the nateglinide-treated patients showed a significant reduc-F i g u r e 3 .…”

Section: O F T H E S T U D Y I N Gl I B E N C L a Mi D E Gr O U Pmentioning

confidence: 53%

Effects of Nateglinide and Glibenclamide on Prothrombotic Factors in Naieve Type 2 Diabetic Patients Treated with Metformin: A 1-Year, Double-Blind, Randomized Clinical Trial

et al. 2007

View full text Add to dashboard Cite

Objective (FPI), postprandial plasma insulin (PPI), homeostasis model assessment index (HOMA index), lipid profile with lipoprotein (a) [Lp(a)], fibrinogen (Fg), plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (t-PA), homocysteine (Hcy), systolic blood pressure (SBP), diastolic blood pressure (DBP).Results After 9 months of treatment, both tested drug combinations were similarly associated with a significant reduction in FPG (nateglinide, glibenclamide, both p<0.05) p<0.01), p<0.01, p<0.05), p< 0.05); the glibenclamide group, showed a significant reduction in HbA1c p<0.05), p< 0.05), p<0.05), and HOMA index (-23.9%, p<0.05) but to a minor extent. Moreover, the HbA1c difference value from baseline observed in the nateglinide-treated group was significantly higher than that observed in the glibenclamide group. Therefore the nateglinide-treated patients showed a significant reduction in some prothrombotic parameters all p<0.05), whereas the glibenclamide-treated patients did not. Conclusion Nateglinide appears to improve glycemic control as well as the levels of some prothrombotic parameters compared to glibenclamide when administered in combination with metformin.

show abstract

Section: O F T H E S T U D Y I N Gl I B E N C L a Mi D E Gr O U Pmentioning

confidence: 53%

Effects of Nateglinide and Glibenclamide on Prothrombotic Factors in Naieve Type 2 Diabetic Patients Treated with Metformin: A 1-Year, Double-Blind, Randomized Clinical Trial

et al. 2007

View full text Add to dashboard Cite

show abstract

“…2). The additive effects of nateglinide and metformin in combination were further confirmed in a trial of 467 patients with inadequate glycaemic control, after dietary intervention (HbA 1c 6.8-11%) and despite receiving maximal metformin dosages (≥1.5 g/day) [37]. Nateglinide (60 or 120 mg before main meals) dose-dependently reduced HbA 1c with the greatest reduction being observed in patients with the highest baseline values of HbA 1c (Fig.…”

Section: New Approaches To Combination Therapymentioning

confidence: 64%

“…These agents act directly on pancreatic beta cells to stimulate insulin release and reduce postprandial hyperglycaemia [34,35,36,37,38]. Their mode of action is complementary to agents that target insulin resistance.…”

Section: New Approaches To Combination Therapymentioning

confidence: 99%

Rationale and options for combination therapy in the treatment of Type 2 diabetes

Gaal

Leeuw

2003

Diabetologia

Self Cite

View full text Add to dashboard Cite

Pharmacological therapy for Type 2 (non-insulin-dependent) diabetes mellitus aims at controlling hyperglycaemia to delay or prevent complications associated with the disease. Most patients with Type 2 diabetes present with both stimulated insulin deficiency and insulin resistance. In general, the former can manifest as postprandial hyperglycaemia and the latter as fasting hyperglycaemia, though a definitive association has not been established. Emerging data show a high failure rate of long-term monotherapy and establishes the significance of mealtime glycaemia and the role of postprandial glucose excursions in the development and progression of vascular complications. To overcome such failures of monotherapy and to address the different underlying defects of the pathology of Type 2 diabetes, a combined therapy of oral antidiabetic agents with complementary modes of action should be considered. Currently used oral antidiabetic agents such as sulphonylureas, biguanides (metformin) and the thiazolidinediones (rosiglitazone, pioglitazone) commonly target fasting hyperglycaemia and have limited additive effects on postprandial glycaemia. In contrast, α-glucosidase inhibitors can reduce postprandial hyperglycaemia but gastrointestinal side effects restrict their use. The development of new agents to control postprandial glucose excursions could be considered as an additional objective for the management of Type 2 diabetes. To this end new short-acting enhancers of insulin secretion such as repaglinide (benzoic acid derivative) and nateglinide (amino acid derivative) have been developed. The combination of such agents with other complementary modes of action, e.g. an insulin sensitizer, could target better major underlying defects of Type 2 diabetes and thereby provide a better approach for controlling the entire glycaemic risk. [Diabetologia (2003)

show abstract

“…The glucose-lowering extent of metformin is additive when used in combination with a sulphonylurea, [28][29][30][31][32][33][34] a meglitinide, 35 a thiazolidinedione [36][37][38][39][40][41][42][43][44][45] or an α-glucosidase inhibitor. 20,[46][47][48] A one-year study demonstrated equivalent antihyperglycaemic efficacy with a metformin-sulphonylurea combination compared with a pioglitazone-sulphonylurea combination in patients inadequately controlled on a sulphonylurea alone.…”

Section: Metformin In Combinationmentioning

confidence: 99%

Metformin therapy and clinical uses

Scarpello

Howlett

2008

Diabetes and Vascular Disease Research

290

225

View full text Add to dashboard Cite

Metformin is now established as a first-line antidiabetic therapy for the management of type 2 diabetes. Its early use in treatment algorithms is supported by lack of weight gain, low risk of hypoglycaemia and its mode of action to counter insulin resistance. The drug's anti-atherosclerotic and cardioprotective effects have recently been confirmed in prospective and retrospective studies, and appear to reflect a collection of glucose-independent effects on the vascular endothelium, suppressant effects on glycation, oxidative stress and formation of adhesion molecules, stimulation of fibrinolysis and favourable effects on the lipid profile. Although avoidance of troublesome gastrointestinal tolerability issues requires careful dose titration, the risk of serious adverse events is considered low provided that contra-indications (especially with respect to renal function) are observed. As many of its actions go beyond glucose lowering, emerging evidence indicates potential benefits in other insulin-resistant states and possibly tumour suppression.

show abstract

Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients

Cited by 59 publications

References 29 publications

Effects of Nateglinide and Glibenclamide on Prothrombotic Factors in Naieve Type 2 Diabetic Patients Treated with Metformin: A 1-Year, Double-Blind, Randomized Clinical Trial

Effects of Nateglinide and Glibenclamide on Prothrombotic Factors in Naieve Type 2 Diabetic Patients Treated with Metformin: A 1-Year, Double-Blind, Randomized Clinical Trial

Rationale and options for combination therapy in the treatment of Type 2 diabetes

Metformin therapy and clinical uses

Contact Info

Product

Resources

About